https://www.selleckchem.com/pr....oducts/cdk2-inhibito
The best response in 6 cycle chemotherapy was complete 8 (22%), partial 24 (68%), and stable disease 3 (8%). All patients had trastuzumab maintenance (median cycle 13; range 7-51), and 49% of the patients had capecitabine with trastuzumab (median capecitabine cycle 6; range 2-3. The median PFS of the patients was 12.0months (95% CI 10.3-13.7), and median OS was 17.4months (95% CI 15.2-19.5). There were 2 patients with grade 1 cardiotoxicity. Trastuzumab maintenance ± capecitabine after 6 cycles of trastuzumab plus combined c
Like
Comment
Share
